Dr Pierre Meulien, executive director of the Innovative Medicines Initiative (IMI), the world’s largest life science public-private partnership between the European Union and the European pharmaceutical industry, shares the incredible work IMI has been doing through the COVID-19 pandemic, along with the critical importance of public-private partnerships for areas like vaccines and antimicrobial resistance (AMR), and gives an exciting preview of IMI’s next strategic plan.
PPPs are not for everyone nor for everything – but for certain topics, they are the only way to make progress and tackle some huge challenges
